Background: Severe gingival overgrowth (GO) is induced in patients taking cyclosporin A (CsA) following organ transplantation. Determining which patient will develop GO is still not possible. The purpose of this study was to establish an association between CsA and gingival overgrowth in heart transplant patients taking into account periodontal and microbiological conditions.

Methods: Thirty patients (10 female, 20 male; range: 13 to 67 years; mean age: 44.89) undergoing CsA treatment were evaluated using the gingival index (GI), plaque index (PI), probing depth (PD), and clinical attachment level (CAL). Subgingival samples collected from the deepest site of each quadrant and saliva samples were submitted to microbial analysis. All patients had at least 12 teeth. Exclusion criteria were the use of antibiotics and/or having undergone periodontal treatment 6 months prior to the study. Patients were divided in two groups: with gingival (GO+) and without gingival overgrowth (GO-).

Results: There were no statistically significant differences between the GO+ and GO- groups when CsA dosage, time since transplant, GI, PI, PD, and CAL were compared. Microbiological examination of the subgingival samples detected the following microorganisms: Actinobacillus actinomycetemcomitans (23%), Porphyromonas gingivalis (36%), Prevotella intermedia (93%), Fusobacterium sp. (66%), Campylobacter rectus (30%), Micromonas micros (66%), enteric rods (0%), and yeasts (30%). A positive association between M. micros and the GO+ group was found (P < 0.001). Yeasts were detected in 30% of the subgingival and saliva samples.

Conclusions: Clinical parameters were not sufficient to determine which patients would develop GO. However, colonization by M. micros might play a role in the etiology of GO.

Download full-text PDF

Source
http://dx.doi.org/10.1902/jop.2004.75.7.918DOI Listing

Publication Analysis

Top Keywords

gingival overgrowth
16
overgrowth heart
8
heart transplant
8
transplant patients
8
patients cyclosporin
8
subgingival samples
8
patients
7
gingival
6
relationship subgingival
4
subgingival salivary
4

Similar Publications

Gingival Debulking Surgery for a Child With Severe Aplastic Anemia: A Case Report.

Spec Care Dentist

January 2025

Paediatric Dentistry, The University of Western Australia, Dental School, Perth, Australia.

Introduction: Aplastic anemia (AA) is a rare condition that frequently manifests with pancytopenia. Management of severe disease is through either allogenic stem cell transplantation or immunosuppressive therapy with supportive care. Drug-induced gingival overgrowth (DIGO) is a potential complication of a number of medications, including cyclosporine and amlodipine.

View Article and Find Full Text PDF

Background: Complicated crown-root fracture (CRF) involves severe injury to the crown, root, and pulp, and may be accompanied by multiple root fractures. The loss of a tooth has lifelong consequences for children and teenagers, but the maintenance of pulp health and the calcific healing of multiple root fractures are rarely reported in the literature.

Case Summary: This case reports healing of a permanent tooth with complicated crown-root and additional root fractures, in which pulp health was maintained.

View Article and Find Full Text PDF

Marked Gingival Overgrowth Protruding from the Oral Cavity Due to Sodium Valproate.

Diagnostics (Basel)

January 2025

Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi 260-8670, Chiba, Japan.

Drug-induced gingival overgrowth is associated with various systemic diseases, including epilepsy. Among antiepileptic medications, phenytoin is commonly reported to cause this condition. In contrast, sodium valproate (VPA), another widely used antiepileptic drug, rarely induces gingival overgrowth.

View Article and Find Full Text PDF

Gingival enlargements are mostly plaque-induced. Other than plaque, a few genetic conditions also cause enlargements of the gingiva. In recent years, there has been a notable rise in drug-induced gingival overgrowth (DIGO) linked to the increased use of medications for various systemic conditions.

View Article and Find Full Text PDF

: Although BRAF inhibitors, such as vemurafenib, produce a marked response in patients with advanced melanoma with a BRAF V600 mutation, they eventually develop resistance to this treatment. To address this issue, vemurafenib is increasingly combined with the MEK inhibitor cobimetinib, leading to improved response rates and enhanced survival. However, this treatment modality is associated with numerous side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!